Gyre Therapeutics Inc. (GYRE) — Cash Flow Reinvestment Rate

Latest as of September 2025: 0.41x

Gyre Therapeutics Inc. (GYRE) has a Cash Flow Reinvestment Rate of 0.41x as of September 2025, reinvesting $1.93 Million (capex $683.00K plus investments $-1.25 Million) from operating cash flow of $4.68 Million. Explore GYRE capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.41x
(Capex + Investments) / Operating CF

Total Reinvested

$1.93 Million
Capex + Investments

Operating Cash Flow

$4.68 Million
USD

Capital Expenditures

$683.00K
USD

Gyre Therapeutics Inc. Cash Flow Reinvestment Rate (2007–2023)

Historical reinvestment intensity for Gyre Therapeutics Inc. across 4 annual periods. Also explore Gyre Therapeutics Inc. assets under control for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Gyre Therapeutics Inc. (2007–2023)

Year-by-year capital reinvestment analysis for Gyre Therapeutics Inc.. For live market cap and broader valuation context, see Gyre Therapeutics Inc. (GYRE) market capitalisation.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2023 1.09x $28.35 Million $25.89 Million $8.59 Million ▼ -37.9%
2022 1.76x $18.81 Million $10.68 Million $5.00 Million ▲ +7259.4%
2010 0.02x $3.31 Million $138.30 Million $3.31 Million ▼ -88.0%
2007 0.20x $4.94 Million $24.84 Million $4.94 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow